Sleep Characteristics and Risk of Alzheimer's Disease: a Systematic Review and Meta-analysis of Longitudinal Studies
Affiliations
Background: Alzheimer's disease (AD) is on the rise in our aging society, making it crucial to identify additional risk factors to mitigate its increasing incidence. This systematic review and meta-analysis aimed to provide updated evidence regarding the association between sleep and AD.
Methods: We conducted a comprehensive search of MEDLINE, EMBASE, and Web of Science databases from inception to July 2023 to identify longitudinal studies. Adjusted relative risks were pooled for each sleep characteristic, and a dose-response analysis was performed specifically for sleep duration.
Results: A total of 15,278 records were initially retrieved, and after screening, 35 records were ultimately included in the final analysis. The results showed that insomnia (RR, 1.43; 95%CI, 1.17-1.74), sleep-disordered breathing (RR, 1.22; 95%CI, 1.07-1.39), as well as other sleep problems, including sleep fragmentation and sleep-related movement disorders, were associated with a higher risk of developing AD, while daytime napping or excessive daytime sleepiness (RR, 1.18; 95%CI, 1.00-1.40) only exhibited a trend toward a higher risk of AD development. Furthermore, our analysis revealed a significant association between self-reported sleep problems (RR, 1.34; 95%CI, 1.26-1.42) and the incidence of AD, whereas this association was not observed with sleep problems detected by objective measurements (RR, 1.14; 95%CI, 0.99-1.31). Moreover, both quite short sleep duration (< 4 h) and long duration (> 8 h) were identified as potential risk factors for AD.
Conclusions: Our study found the association between various types of sleep problems and an increased risk of AD development. However, these findings should be further validated through additional objective device-based assessments. Additional investigation is required to establish a definitive causal connection between sleep problems and AD.
Space exploration and risk of Parkinson's disease: a perspective review.
Ali N, Beheshti A, Hampikian G NPJ Microgravity. 2025; 11(1):1.
PMID: 39753605 PMC: 11698718. DOI: 10.1038/s41526-024-00457-6.
Kaliman P, Alvarez-Lopez M, Lehodey A, Fernandez D, Chocat A, Schlosser M Biol Psychiatry Glob Open Sci. 2024; 5(1):100398.
PMID: 39582797 PMC: 11585798. DOI: 10.1016/j.bpsgos.2024.100398.
Mace R, Law M, Cohen J, Ritchie C, Okereke O, Hoeppner B JMIR Res Protoc. 2024; 13:e64149.
PMID: 39571150 PMC: 11621724. DOI: 10.2196/64149.
Carpi M, Mercuri N, Liguori C Drugs. 2024; 84(11):1365-1378.
PMID: 39365407 PMC: 11602839. DOI: 10.1007/s40265-024-02096-3.